AorTx, a secretive Redwood City company developing a aortic valve replacement technology, has raised $5.8 million in two rounds of funding.
LinkSV reported the company raised $2.7 million earlier this year, and VentureWire reported (sub required) it has just raised more in first round, for a total of $5.8 million.
The company is moving from animal to human trials.
Investors include Bio-Star Private Equity Fund, Saratoga Ventures, MedFocus, Wilson Sonsini Goodrich & Rosati and St. Jude Medical.
Tags: co:AorTx, inv:Bio-Star-Private-Equity-Fund, inv:MedFocus, inv:Saratoga-Ventures, inv:St.-Jude-Medical, inv:Wilson-Sonsini-Goodrich-&-Rosati
5:41 am
VentureBeat » Life sciences briefing: Friday, Oct. 19, 2007 said:
[...] field happens to be booming — we’ve previously covered competitors JenaValve, AorTx and [...]
5:29 pm
VentureBeat » Life sciences briefing: Monday, Nov. 19, 2007 said:
[...] previous coverage of the company is here. AorTx had previously raised $5.8 million in two funding rounds, so the deal represents a decent [...]